The iMODERN trial compared immediate revascularization of nonculprit lesions in STEMI patients using iFR with delayed revascularization based on stress perfusion CMR up to 6 weeks after the index procedure. It included 1146 patients after successful primary PCI with at least one nonculprit lesion, randomly assigned to iFR (n=558) or CMR (n=588). In the iFR group, 237 out of 556 patients (42.6%) underwent PCI of nonculprit lesions, in the CMR group 110 out of 587 patients (18.7%). The primary endpoint—a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure at 3 years—occurred in 9.3% of patients in the iFR group and 9.8% in the CMR group (HR 0.95; 95% CI 0.65-1.40). Secondary outcomes such as cardiac death (1.9% vs. 2%), target lesion failure (10.2% vs. 10.5%), and unstable angina (3.3% vs. 3.9%) were similar in both groups. Serious adverse events occurred in 145 patients in the iFR group and 181 in the CMR group. Immediate iFR-guided PCI was not superior to delayed CMR-guided PCI.[2][3]